Oramed Pharmaceuticals Inc (NASDAQ:ORMP)
| 6.00 Data as of 3:59pm ET |  -0.40 / -6.25%Today’s Change | 2.76 Today|||52-Week Range 10.68 | +51.52% Year-to-Date |
Latest ORMP News | Press Releases
No recent news for Oramed Pharmaceuticals Inc.
Today’s Trading
| Previous close | 6.40 |
| Today’s open | 6.08 |
| Day’s range | 6.00 - 6.55 |
| Volume | 93,475 |
| Average volume (3 months) | 39,932 |
| Market cap | $46.2M |
| Dividend yield | -- |
Data as of 3:59pm ET, 06/19/2013
Growth & Valuation
| Earnings growth (last year) | -150.00% |
| Earnings growth (this year) | -- |
| Earnings growth (next 5 years) | -- |
| Revenue growth (last year) | -- |
| P/E ratio | NM |
| Price/Sales | -- |
| Price/Book | 11.30 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| CMXICytomedix Inc | +0.04 | +8.89% |
| DMPIDelMar Pharmaceutica... | 0.00 | 0.00% |
| VTUSVentrus Biosciences ... | +0.02 | +0.91% |
| RGDXResponse Genetics In... | -0.02 | -1.32% |
Data as of 4:00pm ET, 06/19/2013
Financials
| Next reporting date | -- |
| EPS forecast (this quarter) | -- |
| Annual revenue (last year) | $0.00 |
| Annual profit (last year) | -$3.3M |
| Net profit margin | -- |
Profile
Sector Health Technology |
Industry Pharmaceuticals: Other |
President, Chief Executive Officer & Director Nadav Kidron, MBA |
Chief Operating Officer & VP-Business Development Joshua Hexter |
Corporate headquarters Jerusalem, -- |
Forecasts
